Protalix Biotherapeutics Inc Cash Flow-to-Debt Ratio
Protalix Biotherapeutics Inc cash flow-to-debt ratio. Protalix Biotherapeutics Inc (PLX) has a Cash Flow-to-Debt Ratio of 0.06x as of December 2025, meaning its operating cash flow of $2.03 Million could theoretically repay 0% of its total liabilities ($34.12 Million) in one year. Check cash flow quality index of Protalix Biotherapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Protalix Biotherapeutics Inc (1996–2025)
Cash flow-to-debt ratio of Protalix Biotherapeutics Inc from 1996 to 2025. Historical debt coverage capacity for Protalix Biotherapeutics Inc across 30 annual periods. Check PLX capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Protalix Biotherapeutics Inc Cash Flow-to-Debt Ratio by Year (1996–2025)
Protalix Biotherapeutics Inc cash flow-to-debt ratio by year from 1996 to 2025. Year-by-year debt coverage analysis for Protalix Biotherapeutics Inc. For the full cash flow conversion analysis, see cash efficiency ratio of Protalix Biotherapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.35x | $-11.99 Million | $34.12 Million | ▼ -222.4% |
| 2024 | 0.29x | $8.67 Million | $30.21 Million | ▲ +1208.2% |
| 2023 | -0.03x | $-1.32 Million | $50.87 Million | ▲ +93.1% |
| 2022 | -0.38x | $-25.00 Million | $66.43 Million | ▼ -191.6% |
| 2021 | -0.13x | $-10.29 Million | $79.70 Million | ▲ +53.1% |
| 2020 | -0.27x | $-26.11 Million | $94.97 Million | ▼ -64.3% |
| 2019 | -0.17x | $-19.36 Million | $115.71 Million | ▼ -146.4% |
| 2018 | -0.07x | $-7.74 Million | $114.01 Million | ▲ +29.7% |
| 2017 | -0.10x | $-9.99 Million | $103.51 Million | ▲ +72.3% |
| 2016 | -0.35x | $-32.10 Million | $92.20 Million | ▼ -23.8% |
| 2015 | -0.28x | $-24.28 Million | $86.38 Million | ▼ -28.7% |
| 2014 | -0.22x | $-29.28 Million | $134.07 Million | ▲ +0.1% |
| 2013 | -0.22x | $-30.65 Million | $140.28 Million | ▼ -2924.7% |
| 2012 | 0.01x | $635.00K | $82.08 Million | ▲ +102.6% |
| 2011 | -0.30x | $-23.57 Million | $77.88 Million | ▲ +40.2% |
| 2010 | -0.51x | $-38.46 Million | $76.05 Million | ▼ -194.2% |
| 2009 | 0.54x | $44.45 Million | $82.79 Million | ▲ +121.7% |
| 2008 | -2.48x | $-16.02 Million | $6.46 Million | ▼ -5.6% |
| 2007 | -2.35x | $-10.45 Million | $4.45 Million | ▼ -24.7% |
| 2006 | -1.88x | $-5.09 Million | $2.70 Million | ▼ -89.5% |
| 2005 | -0.99x | $-72.47K | $72.93K | ▲ +58.3% |
| 2004 | -2.39x | $-168.12K | $70.47K | ▼ -37.6% |
| 2003 | -1.73x | $-136.68K | $78.82K | ▲ +6.5% |
| 2002 | -1.85x | $-146.59K | $79.07K | ▲ +81.9% |
| 2001 | -10.22x | $-789.43K | $77.28K | ▼ -10683.7% |
| 2000 | -0.09x | $-53.11K | $560.61K | ▲ +96.9% |
| 1999 | -3.07x | $-1.41 Million | $459.36K | ▼ -378.0% |
| 1998 | -0.64x | $-909.52K | $1.42 Million | ▼ -1831.8% |
| 1997 | -0.03x | $-247.92K | $7.47 Million | ▼ -500.7% |
| 1996 | -0.01x | $-40.57K | $7.34 Million | — |